Transcription of expanded microsatellite repeats is associated with multiple human diseases, including myotonic dystrophy, Fuchs' endothelial corneal dystrophy, and C9orf72-ALS/FTD.
Introduction
Microsatellite expansion diseases are a class of genetically inherited conditions associated with the destabilization and expansion of short repetitive sequence elements in the genome, which cause pathogenic effects via multiple mechanisms including epigenetic silencing, RNA gain of function, and/or protein gain of function 1 . These diseases, which include myotonic dystrophy Muscleblind-like (MBNL) proteins away from their endogenous RNA targets 4 leading to aberrant splicing patterns 5 and altered RNA stability/localization 6, 7 , among other effects. In C9ALS/FTD, expanded G 4 C 2 and C 4 G 2 repeat RNAs sequester several RNA binding proteins, as well as undergo RAN translation to produce dipeptide polymers toxic to cells [8] [9] [10] . Taken together, these findings suggest that silencing of the expanded repeat locus holds therapeutic value.
Various approaches have been taken to silence toxic RNA or protein in microsatellite expansion diseases, including antisense oligonucleotides 5, [11] [12] [13] , small RNAs [14] [15] [16] [17] , and small molecules 18, 19 .
Perturbation to co-factors of RNA polymerase II (RNA Pol II) reduces transcription through expanded repeats in HD 20 and C9ALS/FTD 21 models, and treatment with Actinomycin D at nanomolar doses preferentially impedes transcription of CTG repeats in DM models 18 . A prevailing hypothesis is that the efficiency of transcription through expanded repeats is decreased relative to non-repetitive sequences. This would provide a therapeutic window through which to impede transcription of these sequences in a repeat length-dependent manner resulting in premature termination and nascent transcript turnover.
A deactivated version of the Cas9 enzyme, of the clustered regularly interspaced short palindromic repeats (CRISPR) system, has been used to impair transcription of specific loci, as well as to visualize, tether, and/or isolate DNA in a sequence-specific manner. In prokaryotes, deactivated Cas9 (dCas9) can efficiently inhibit transcriptional initiation and elongation when bound to gene bodies or promoters 22 . In eukaryotes, dCas9 can inhibit transcriptional initiation when fused to an inhibitory domain and targeted near the transcription initiation site [23] [24] [25] [26] .
However, elongation inhibition by targeting dCas9 alone to the gene body has been largely ineffective, even when recruiting dCas9 to > 90 possible targeting sites 27 .
Here, we test the hypothesis that expanded microsatellite repeats are highly sensitive to transcriptional blockade by dCas9, even in the context of processively elongating RNA Pol II. We find that the efficiency of inhibition follows rules similar to that observed in non-repetitive contexts, with clear dependencies on proto-spacer adjacent motif (PAM) sequence and the targeted DNA strand. In addition, application of this approach to cell and animal models of disease rescues downstream pathogenic consequences. These observations present a novel application of the CRISPR/Cas9 system, provide new tools to impede transcription of expanded microsatellites in a strand-dependent manner, and suggest that targeting transcription in a repeat length-dependent manner may be a viable therapeutic strategy for these diseases.
Results

dCas9-gRNA complexes reduce abundance of repeat-containing RNAs in a length-, PAM-, and strand-dependent manner
Binding of deactivated S. pyogenes Cas9 (dCas9) to DNA in the vicinity of transcriptional start sites (TSSs) can inhibit transcription in prokaryotes and eukaryotes when coupled with a transcriptional inhibitory domain. However, inhibition of transcriptional elongation via gene body targeting (>1kb away from TSS) has been relatively inefficient in eukaryotes. We hypothesized that transcriptional inhibition of expanded microsatellite repeats by dCas9 would be more potent as the repetitive nature of these repeats, sometimes thousands of tandem copies, would: 1) present challenges for RNA Pol II elongation even under normal conditions; and 2) allow for high levels of dCas9 recruitment using a single guide RNA (gRNA) sequence forming a substantial block to the elongating polymerase ( Fig. 1A) . To test this model, we employed a plasmid-based strategy in cell culture to examine the effects of dCas9 recruitment on transcription of CTG/CAG repeats that occur in DM1, FECD, HD, and SCAs. We utilized plasmids containing 0, 12, 40, 240, 480, or 960 CTG repeats located >1.5 kilobases downstream of the TSS in the DMPK 3' UTR. To recruit dCas9 to these repeats, we designed gRNAs targeting CTG/CAG repeats in each of 3 possible nucleotide phases of the non-template strand, and 1 phase of the template strand ( Fig   1B, left panel) . Each CRISPR PAM was, therefore, constrained to CAG, AGC, GCA, or CTG. To precisely measure the expression of the repeat transcripts, we developed an amplicon-based deep sequencing assay called "Measurement of Barcoded Transcripts by Amplicon Sequencing"
(MBTA-Seq) ( Fig. S1 ). For this assay, we modified the plasmids by introducing distinct 8 nucleotide barcodes downstream of each CTG repeat tract. RNA was harvested from cells transfected with these plasmids, polyA+ selected, amplified by RT-PCR across the barcode region but avoiding the repeat containing region, and deep sequenced ( Fig. S1 ). This assay was highly reproducible, and allowed us to simultaneously measure the expression of multiple repeatcontaining transcripts in the same pool of cells (Table S1 ). In the presence of dCas9 and (CAG) 6 gRNA, we observed a dramatic reduction in expression of RNAs containing expanded CUG repeats ( Fig. 1B, right panel) . Knockdown efficiency increased as a function of the number of repeats present, presumably as a function of the number of dCas9-gRNA complexes that could be recruited. Twelve CTG repeats, likely recruiting at most a single dCas9-gRNA complex, showed ~50% repeat-containing RNA remaining, and 40 CTG repeats showed ~25% remaining.
Repeat lengths >240 CTG showed only ~5% remaining. (AGC) 6 and (GCA) 6 gRNAs showed poor knockdown efficiency, consistent with previously described SpCas9 PAM preferences, where NGG is best, NAG is second best, and NCG/NTG are equally disfavored 28 . The (CUG) 6 gRNA showed little to no knockdown of transcripts containing expanded CUG repeats, potentially due to a weak PAM as well as targeting to the template strand. Importantly, dCas9 was required for decreased expression of repeat-containing transcripts, as presence of gRNAs alone did not lead to knockdown (Fig. S2A) .
These observations suggest that recruitment of dCas9-gRNA complexes can impede transcription of expanded microsatellite repeat tracts in a repeat length-dependent manner.
However, these experiments were performed using transiently transfected plasmids, which may not accurately model all aspects of transcriptional regulation in a genomic context. Furthermore, experiments to assess binding of protein complexes to DNA loci are most commonly performed using genomic targets and not plasmids. Therefore, we established a HeLa cell line in which transgenes for each of the 6 CTG repeat lengths, with associated barcodes, were stably integrated ( Fig. S2B) . To measure DNA binding by dCas9-gRNA complexes, we performed chromatin immunoprecipitation (ChIP) against dCas9 in the presence of (CAG) 6 gRNA or nontargeting control gRNA. We used deep sequencing of barcodes, similar to MBTA-Seq, to quantitate abundance of immunoprecipitated DNA encoding each repeat length. To also confirm transcriptional repression in this cell line, we measured RNA abundance by MBTA-Seq following transfection of dCas9-gRNA complexes. We observed that relative dCas9-gRNA binding to the DNA increased as a function of repeat length, concomitant with a decrease in relative RNA abundance (Fig. 1C) . In this genomic context, dCas9-gRNA reduced the abundance of transcripts containing 960 CUG repeats to ~20%, and was associated with ~8-fold increased binding relative to genomic loci with no CTG repeat tracts. These observations suggest that binding of dCas9-gRNA complexes to DNA impedes transcription of repeat tracts, and that both binding and potency of transcriptional inhibition increases with the number of repeats.
To test the ability of dCas9-gRNA complexes to impede transcription of other repeat-containing sequences, we assayed CCTG repeat tracts, which cause DM2. dCas9-gRNA complexes similarly reduced expression of CCUG repeat-containing RNAs (Fig. 1D) . Here, the tetranucleotide repeat allowed testing of four distinct gRNAs targeting the non-template strand, (CAGG) 5 , (AGGC) 5 , (GGCA) 5 , and (GCAG) 5 , corresponding to PAMs AGG, GGC, GCA, and CAG, respectively. Consistent with PAM preferences of SpCas9, knockdown was most efficient with the (CAGG) 5 gRNA, although the (AGGC) 5 and (GCAG) 5 gRNAs were also quite effective.
The (CCUG) 5 gRNA was not effective at impeding transcription of CCTG repeats. Similar to our studies of expanded CUG repeats, presence of gRNAs alone did not lead to knockdown (Fig.   S2C ).
In both bacterial and mammalian systems, blockade of RNA Pol II has been shown to be most effective when targeting dCas9 to the non-template strand of transcribed DNA, likely because helicase activity native to RNA Pol II can unwind nucleic acids hybridized to the template strand 22 .
Our results from targeting repeats with (CAG) 6 gRNA versus (CUG) 6 gRNA and (CAGG) 6 gRNA versus (CCUG) 6 gRNA are consistent with this model, but these comparisons involve changes to both the targeted strand as well as the PAM. In addition, some of the most efficient gRNAs are those that could also facilitate dCas9 targeting of RNA via complementarity between the gRNA and the repeat-containing RNA. To study how the PAM sequence and targeted strand influence the efficacy of transcriptional blockade in isolation, and to clarify DNA versus RNA-targeting mechanisms, we generated (CAG) 960 and (CAGG) 240 plasmids suitable for MBTA-Seq. These constructs are identical to their (CTG) 960 and (CCTG) 240 repeat-containing counterparts except for their repeat tract and barcode sequences. We then used MBTA-Seq to measure the efficiency of CUG 960 or CAG 960 knockdown in the presence of either (CAG) 6 or (CUG) 6 gRNA ( Fig. 1E) . By testing all four combinations, we could separate PAM-dependent effects from strand-dependent effects. Consistent with previous reports, targeting the non-template DNA strand reduced expression more effectively than targeting the template strand. Specifically, (CUG) 960 was reduced to ~5% by a (CAG) 6 gRNA, while (CAG) 960 was reduced to ~40% by the same gRNA.
These two conditions effectively compare targeting of non-template vs. template strand, controlling for the CAG PAM. Similarly, (CAG) 960 was reduced to ~50% by the (CUG) 6 gRNA, and (CUG) 960 remained relatively high at ~97%. Again, targeting of the non-template strand is more efficient than targeting of the template strand, controlling for the CTG PAM.
PAM-dependent effects were quantified by comparing abundance of (CTG) 960 in the presence of (CAG) 6 gRNA relative to abundance of (CAG) 960 in the presence of (CUG) 6 gRNA. Here, both gRNAs target the non-template strand, but use different PAMs. We observed ~5% RNA remaining with the CAG PAM, and ~55% RNA remaining with the CTG PAM, controlling for targeted strand, consistent with the CAG PAM being more effective. Similarly, measurement of (CAG) 960 RNA in the presence of (CAG) 6 gRNA and (CTG) 960 RNA in the presence of (CUG) 6 gRNA allows comparison of both PAMs, controlling for targeted strand. Again, we observed more effective silencing with a CAG PAM (~40% RNA remaining) as compared to the CTG PAM (no change in RNA). We observed similar trends with CCTG/CAGG repeats ( Fig. 1F) showing CUG-containing RNA foci, as well as a reduction in the number of foci per cell ( Fig. 2A,   B ). We measured the extent to which MBNL-dependent splicing misregulation, characteristic of DM1 cells [30] [31] [32] , could be rescued using a splicing minigene reporter containing MBNL1 exon 5 33 .
The percent spliced in (psi, Y) of this exon is regulated by MBNL proteins, and changes from 10% in healthy HeLa cells to ~70% in cells expressing (CUG) 480 repeats. Co-transfection of dCas9 and (CAG) 6 gRNA partially rescued splicing dysregulation, reducing Y to ~35% (Fig. 2C) .
This rescue occurred only in the presence of both dCas9 and (CAG) 6 gRNA, indicating that (CAG) 6 gRNA expression alone cannot neutralize toxic CUG RNA by directly hybridizing to repeat RNA and displacing MBNL protein or facilitating degradation by dsRNA-sensitive nucleases. It is well established that splicing defects in DM1 depend on the extent of MBNL sequestration and therefore total CUG repeat load; Y values for MBNL1 exon 5 increased with the length of the CTG repeat tract transfected into cells ( Fig. 2D ) 34 . Interestingly, co-expression of dCas9 and (CAG) 6 gRNA yielded a similar rescue of splicing across all repeat lengths exhibiting mis-splicing, i.e. 240, 480, and 960 CUG repeats.
The CTG, CCTG, and G 4 C 2 repeats associated with DM1, DM2, and C9ALS/FTD, respectively, undergo repeat-associated non-ATG (RAN) translation 9,10 (Zu et al, submitted 2017). We hypothesized that reduction in repeat-containing RNA abundance by dCas9-gRNA complexes would yield reduced RAN protein abundance. We assessed this by performing western analyses of RAN peptides robustly expressed from CTG, CCTG and G 4 C 2 repeat containing plasmids transfected into HEK293T cells. Detection of the RAN products is facilitated by the presence of multiple tags downstream of the repeats, one in each coding frame ( Fig. 2E) . In all three western analyses, RAN proteins were observed only in the presence of repeat-containing plasmids, and were slightly reduced upon expression of a control, non-targeting gRNA, likely due to competition of plasmids for transcriptional machinery. Consistent with measurements of CUG-containing RNA levels ( Fig. 1B) , the FLAG-tagged poly-Ala peptide translated from CUG repeats was dramatically reduced in the presence of (CAG) 6 gRNA, and modestly reduced in the presence of (CUG) 6 gRNA ( Fig. 2E) . Importantly, the RAN protein was not reduced in the presence of (CAG) 6 gRNA alone without dCas9 ( Fig. S2D) . HA-tagged poly-LPAC translated from CCUG repeats was dramatically reduced in the presence of (CAGG) 5 , (AGGC) 5 , and (GCAG) 5 gRNAs ( Fig. 2F) , but not in the presence of (CCUG) 5 gRNA ( Fig. S2E) . To test the effects of dCas9 on levels of poly-GlyPro translated from G 4 C 2 repeats, we designed two gRNAs with NGG PAMs: (C 4 G 2 ) 3 that would target the non-template strand and (G 4 C 2 ) 3 that would target the template strand.
Consistent with our studies of CTG and CCTG repeats, dCas9-gRNA complexes targeted to (G 4 C 2 ) 120 exhibited silencing of RAN peptide in a strand-dependent manner (Fig. 2G) , and did not occur in the presence of gRNA alone ( Fig. S2F) . While reduction in RAN protein was achieved with both gRNAs, silencing was more effective with gRNA targeting the non-template strand.
dCas9-mediated transcriptional inhibition reduces nuclear RNA foci and rescues splicing defects in human DM1 myoblasts
We next tested whether this approach could impede transcription of expanded repeats in the native DMPK locus, in primary human DM1 myoblasts. To express deactivated Cas9, we generated an adeno-associated virus (AAV) carrying sequences for the Cas9 and gRNAs that can efficiently infect muscle cells. As the traditional dCas9 sequence cannot be accommodated within the limits of the AAV genome, we turned to the smaller S. aureus Cas9 (SaCas9) that can be packaged with a U6 promoter-driven gRNA within the AAV genome 35 . We generated a deactivated SaCas9 (dSaCas9) by mutating catalytic residues D10 and H557 to alanines 36 .
Since dSaCas9 exhibits slightly different PAM preferences to dSpCas9 (NNGRR versus NGG), we used MBTA-Seq to confirm that dSaCas9 with a (CAG) 6 gRNA could impede transcription of expanded CTG repeats in a length-dependent manner (Fig. S3A) . Next, we packaged dSaCas9 with control or (CAG) 6 gRNA into an AAV2/6 virus, as we found that the AAV6 capsid efficiently infects myoblasts in culture ( Fig. S3B) .
We infected a primary DM1 myoblast line with the AAV2/6 encoding dSaCas9 and (CAG) 6 or control gRNAs. Expression of dSaCas9 protein with 5 nuclear localization signals in the infected cells was detected by immunofluorescence against the HA tag and was found to be nuclear, although at times also appeared to be cytoplasmic ( Fig. S3B, Fig. 3A ). We assayed CUG repeat content by FISH and as observed previously in HeLa cells, the number of CUG repeat foci per cell was decreased in the presence of dSaCas9 and (CAG) 6 gRNA, relative to control gRNA ( Fig.   3A, B ).
Although splicing events in DM1 patient muscle have been well characterized, myoblasts in culture do not express many transcripts typically present in mature muscle. To identify molecular changes in cultures that appropriately model in vivo DM1 biology, we further characterized the line described above, as well as a line derived from an individual unaffected by DM1. Four independent RNAseq libraries were created from the DM1 cells grown in several different growth conditions, and two from the unaffected line. To identify splicing changes in these lines that appropriately model those occurring in human DM1 muscle, we first defined a high confidence set of DM1-relevant splicing events by re-analyzing a set of 55 transcriptomes (44 DM1 and 11 unaffected) from human tibialis biopsies (GSE86356). We identified splicing events whose inclusion level, Y, strongly correlated to the concentration of free, functional MBNL protein in the affected tissue, as previously described 34 . We fit sigmoid curves describing the relationship between MBNL concentration and Y, for example for MBNL1 exon 5 (Fig. 3C) . The best-fitting events were selected (see Methods, Fig. S4 ), and their dysregulation (DY, Tibialis anterior, DM1 minus unaffected) was plotted against dysregulation observed in the DM1 myoblasts (DY, Primary myoblast, DM1 minus unaffected) ( Fig. 3D) . These filtering steps yielded a set of events whose behavior is reasonably recapitulated in each system; the correlation in splicing dysregulation between tibialis and myoblasts was ~0.68.
To assess splicing rescue in DM1 myoblasts upon treatment with AAV-dSaCas9 and (CAG) 6 gRNA, we first performed RT-PCR to measure the inclusion level of MBNL1 exon 5. While viral infection with an AAV encoding dSaCas9 and control gRNA yielded a Y of ~50%, infection with AAV encoding dSaCas9 and (CAG) 6 gRNA rescued Y to ~20% (Fig. 3E) . We assessed splicing transcriptome-wide by RNAseq, and analyzed those exons in the myoblasts whose changes are Table S3 ). To assess potential off-target changes in gene expression for other transcripts with genomic CTG or CAG repeat tracts, we treated non-DM1 myoblasts with AAV-dSaCas9 and (CAG) 6 gRNA or control gRNA and performed RNA-Seq. We enumerated the longest contiguous CTG or CAG repeat tracts in all pre-mRNAs in the human genome, and found none to exceed 24 repeats; maximums were 24 CTG in TCF4 and 22 in AR. We observed no differences in gene expression that depended on the length of repeat tracts, for both CTG or CAG repeats ( Fig. S3C, D) .
These observations suggest that dSaCas9 targeted to CTG repeat tracts can impede transcription of expanded CUG repeats, relieve MBNL sequestration, and restore splicing homeostasis in human cells containing DM1 repeat expansions, with selectivity that depends on the extreme repeat lengths commonly found in symptomatic tissue.
dCas9-mediated transcriptional inhibition reduces RNA foci, rescues Clcn1 expression, and decreases myotonia in a mouse model of DM1
We next assessed whether dCas9 could impede transcription of expanded CTG repeats in a wellestablished mouse model of DM1, HSA LR 37 . These mice carry a human skeletal actin transgene containing 250 CTG repeats in the 3' UTR and exhibit molecular, cellular, and phenotypic properties characteristic of DM patients. To assess the efficacy of this approach independently of potential in vivo drug delivery issues, we first dissected extensor digitorum longus muscle (EDL) fibers, and cultured them ex vivo. As CTG repeat expression in this model is driven by the HSA promoter, RNA foci are ubiquitous and numerous in myonuclei (Fig 4A, Top panel) . To assess the extent to which dSaCas9 could reduce RNA foci, we infected cultured individual HSA LR EDL fibers for 2 days and performed RNA FISH against CUG repeats (Fig. 4A) . In untreated HSA LR fibers, we observed robust FISH signal in ~80% of myonuclei. This remained at similar levels in the presence of a dSaCas9 with control gRNA, but was reduced to ~50% in the presence of dSaCas9 with (CAG) 6 gRNA, where any sign of FISH signal in a nucleus was recorded ( Fig. 4B) .
Overall FISH signal intensity, quantitated in >1400 nuclei per condition (see Methods, Fig. S5 ), was dramatically decreased in fibers treated with dSaCas9-(CAG) 6 gRNA relative to control gRNA and untreated fibers (Fig. 4C) . These observations suggest that efficient delivery of dSaCas9-(CAG) 6 to muscle fibers ex vivo is sufficient to significantly reduce RNA foci load within 2 days.
Having observed robust elimination of RNA foci ex vivo, we turned to in vivo experiments. Given previous reports of immune reactivity against Cas9, especially following intramuscular injection 38 , we chose to administer AAV-dSaCas9-gRNA by temporal vein injection at postnatal day 2, prior to full establishment of immune tolerance. AAV2/6 or AAV2/9 carrying dSaCas9 and (CAG) 6 or control gRNA was injected. Five weeks following injection, electromyography was performed to analyze myotonia in tibialis anterior and gastrocnemius muscles ( Fig. 5A) . Wild type FVB mice showed no myotonia, an Mbnl1 KO mouse showed myotonia in 100% of needle insertions, and HSA LR mice showed myotonia in 87-100% of insertions. HSA LR injected with AAV6-dSaCas9control gRNA showed myotonia levels similar to uninjected HSA LR (87%). However, HSA LR injected with AAV6-dSaCas9-(CAG) 6 gRNA showed a reduction in myotonia, with some mice showing myotonia in 33-50% of insertions. Interestingly, nearly all mice injected with AAV2/6
showed rescue while only 1 mouse injected with AAV9 showed rescue ( Fig. S5D) .
Because mis-splicing of chloride channel 1 (Clcn1) is well-established to mediate myotonia in DM1 and in HSA LR mice, we measured splicing patterns of Clcn1 mRNA in treated mice.
Surprisingly, when analyzing RNA extracted from bulk muscle tissue, we could not detect significant rescue in Clcn1 splicing, or other MBNL-dependent splicing events (data not shown).
Because myotonia is measured by assaying individual bundles of fibers, we hypothesized that some regions of muscle may be rescued and not others, and that any potential change in isoform composition in these regions may be diluted in analyses of bulk tissue. This is consistent with a roughly ~2.5-fold increase in myonuclei per fiber over the first 4 weeks of post-natal development, which could also dilute the proportion of myonuclei containing AAV episomes 39 . AAV6-delivered dSaCas9 distribution in EDL fibers, as assessed by immunofluorescence against the HA tag, revealed mosaic expression, with rare fibers showing region-specific nuclear signal for dCas9 ( Fig. 5B) , and most fibers not showing presence of dCas9 at all. Control immunofluorescence experiments against lamin A showed ubiquitous and consistent labeling of all myonuclei, ruling out potential staining artifacts (Fig. S5E) . In spite of mosaic dSaCas9 distribution, 5-15% of fibers showed complete loss of CUG RNA foci ( Fig. 5C ). Furthermore, animals that showed the greatest decrease in RNA foci also showed the strongest myotonia rescue. Reduction of RNA foci load in some nuclei raised the possibility that proper Clcn1 splicing could be achieved in a subset of nuclei, and that these mRNAs may spread locally throughout the fiber to produce functional Clcn1 protein. Indeed, mice treated with (CAG) 6 gRNA showed increased Clcn1 staining at muscle membranes relative to mice treated with control gRNA, but Clcn1 protein was localized only to a subset of fibers per muscle section. These observations are consistent with observations of myotonia elimination in a subset of fibers, yet absence of splicing rescue when assessing bulk tissue (Fig. 5D) . In summary, these experiments suggest that dCas9 can, in principle, rescue disease phenotypes via transcriptional repression, but that widespread rescue of molecular events in muscle will require efficient delivery to a large proportion of myonuclei expressing toxic RNA.
Discussion
The application of CRISPR/Cas9 to genetic diseases is thought to hold great therapeutic promise.
Multiple groups have successfully edited genomes in cell and animal models of disease. Some have directly applied these approaches to microsatellite expansion diseases to remove the expanded repeat tract 40 or cause somatic instability leading to repeat contraction 41 . However, challenges remain to ensure both efficient and specific cleavage activity across multiple cells and tissues of the body. Here, we explore an alternative form of Cas9, dCas9, in which cleavage activity is abrogated. Previous studies demonstrated that dCas9 can successfully reduce transcript levels in prokaryotes and this effect is achieved primarily by blocking elongation of RNA Pol II through the gene body rather than targeting the transcripts themselves 22 . In eukaryotes, however, transcriptional inhibition by recruiting dCas9/gRNA complexes to the gene body was inefficient. As expanded microsatellites are thought to be more challenging for RNA Pol II elongation, we hypothesized that dCas9/gRNA recruitment would effectively impede elongating polymerase. By testing disease-associated repeat sequences across multiple repeat lengths in vitro and in disease models, we demonstrate that dCas9 can substantially reduce repeatcontaining transcript abundance. Importantly, repression efficiency is proportional to repeat length, because longer repeats recruit an increased number of dCas9/gRNA complexes, leading to greater transcriptional blockade ( Fig. 1B-C) .
dCas9 is well established to target DNA 22 , but has also been shown to bind repeat-containing RNA in a gRNA-dependent manner 42 . Indeed, when we immunoprecipitated dCas9 and assessed RNA binding, we observed increased binding to transcripts containing longer repeats (Fig. S2G) .
However, as repeat length increases, the amount of successfully transcribed RNA decreases, suggesting that at long repeat lengths, less RNA remains to be targeted. In the context of disease, microsatellite repeat tracts undergo dramatic somatic expansion in DM1, DM2, C9ALS/FTD, and HD, and evidence suggests that repeat lengths in tissues of symptomatic individuals reach thousands of nucleotides in length 2,3 . Therefore, DNA-based targeting by dCas9 may play a primary role in driving potential therapeutic benefits in individuals with full expansions ( Fig. 6) . At short and intermediate repeat lengths, therapeutic benefit may derive from both DNAand RNA-based targeting by dCas9, to not only impede transcription of repeat-containing DNA, but also modulate downstream consequences of transcribed "escaper" RNAs. Taken together, we demonstrate that dCas9 is an effective tool to limit downstream effects of toxic RNAs and present proof of concept data suggesting that therapeutic benefit can be achieved through this approach.
MBTA-Seq allowed us to rapidly and accurately measure expression of transcripts that are traditionally difficult to assay, in particular across repeat types and repeat lengths in a highly controlled manner. In principle, this approach can be adapted for any collection of transcripts, in Effective, safe delivery in a multi-systemic fashion to sufficient numbers of post-mitotic cells will be necessary for this approach to be therapeutically viable in the context of many of these dominantly inherited neurological diseases. In DM and C9ALS/FTD, it is unclear what fraction of nuclei must be rescued in multi-nucleated muscle or in the central nervous system to halt or improve disease symptoms. Here, we observed that rescue of a subset of nuclei was sufficient to yield partial rescue of myotonia. However, myotonia can be modeled as a loss-of-function event in which Clcn1 protein is lost, and there is evidence that in other recessive muscle diseases, gene editing of a small subset of nuclei can restore sufficient protein expression across muscle fibers to yield therapeutic benefit 43, 44 . Conversely, mis-splicing events yielding pathogenic isoforms with dominant-negative behavior may require full elimination to mitigate deleterious consequences.
Our approach used systemically delivered AAV, which revealed regional variation in transduction efficiency, likely because NLS-tagged Cas9 protein remained restricted to myonuclear domains transduced by AAV episomes, and many new myonuclei are recruited to fibers throughout the first 4 weeks of post-natal muscle development 39 . It is possible that more localized or concentrated delivery would have facilitated transduction of a higher proportion of myonuclei.
Previous studies with AAV-mediated gene therapy typically evaluate expression of proteins that can spread throughout muscle fibers, precluding measurement of transduction efficiency to all myonuclei. Regional variation in rescue is likely to be less relevant with therapies with more homogeneous delivery, for example, small molecules. Nevertheless, reduction of toxic RNA repeat load in a subset of nuclei was sufficient to increase production of Clcn1 protein, with consequences for distant regions of muscle naïve to dCas9. These results emphasize how differences in mechanism of action and delivery efficiency between various therapeutic approaches should significantly influence how we interpret changes in response to those therapies, both at the molecular and phenotypic level.
Finally, while this approach mitigates a key safety concern of CRISPR, which is the unwanted cleavage of off-targets, it also raises questions about whether long-term exposure to dCas9 can be achieved and tolerated, a necessity for repeat expansion diseases. Perhaps most importantly, the ability of dCas9 to impede transcription of microsatellite expansions defines a window in which transcriptional inhibition of expanded repeats is feasible, yet does not interfere with that of typical RNAs. This approach may serve as a baseline with which to compare alternative therapeutic approaches, as well as a tool to identify mechanisms and principles by which transcriptional activity of RNA polymerase II can be modulated in a sequence-specific manner.
Materials and Methods
Cell culture, cell lines and transfection
HeLa and HEK293T cells were cultured in 1X DMEM supplemented with 10% fetal bovine serum and 1% Penicillin/Streptomycin at 37 0 C and 5% CO 2 . The DM1 primary myoblast cells were obtained by G. Xia. The clinical data of research subjects from who muscle biopsies were obtained, have been described before 45 . Muscle biopsies were performed using 7G UCH Muscle Biopsy Needle (#8066, www.cadencescience.com). Samples were cut into small pieces and seeded into a 6cm dish. Myoblasts were expanded at a 1:2 ratio in myoblast growth media (Skeletal Muscle Cell Growth Medium-2, Lonza, #CC 3245) at 37 0 C and 5% CO 2 . For viral transductions, these primary myoblasts were maintained in the growth medium for 3 days and then switched to Differentiation media (DMEM-F12 supplemented with 2% horse serum) for 3 days.
Plasmid DNA transfections of HeLa and HEK293T cells were performed using Trans-IT LT1
(MirusBio) as per manufacturer's instructions. For RNA and FISH analyses, HeLa cells were harvested or processed 72 hours post transfection.
Cloning of barcoded repeat plasmids and gRNA constructs and generation of stable repeat expressing HeLa cell lines
Non-barcoded plasmids carrying 0, 12, 40, 240, 480, 960 CTG repeats (CTG n ) and 960 CAG repeats (CAG 960 ) were kind gifts from Tom Cooper (Baylor College of Medicine). Plasmids with 0 and 12 repeats were modified so that their vector backbones were identical to the others, and carried the ampicillin resistance gene. The (CCTG) 240 plasmid was created as in Philips et al 46 . In brief, oligonucleotide fragments 5'-TCGA(CCTG) 20 C-3' and 5'-TCGAG(CAG) 20 Table S1 .
The dCas9 gRNAs were cloned into an AflII-digested U6 expression vector by annealing oligos as previously described 47 . The dSaCas9 gRNAs were cloned into BsaI -digested vector by annealing oligos as previously described 35 . 
FISH and immunofluorescence analyses
To detect nuclear RNA foci, cells or muscle fibers were fixed with 4% PFA for 10 minutes at room IF analysis to detect dCas9 in mouse muscle fibers from the EDL of mice injected with AAV6-dSaCas9-(CAG) 6 was conducted as described above, except samples were fixed with 100% isopropanol at -20 0 C for 10 mins.
Clcn1 was detected in mouse muscle by performing IF on frozen muscle sections of the TA.
Frozen muscle was sectioned into 10uM slices, fixed with 100% acetone at -20 0 C for 20 minutes, washed with 0.3% Triton X-100-PBS and incubated with rabbit anti Clcn1 (1:100, #CLC11-S, Alpha Diagnostic International) overnight at 4 0 C. Samples were incubated with goat anti-rabbit Alexa Fluor 568 (1:500, Thermo Fisher) for 2 hours at RT and then treated with DAPI and mounted in Vectashield.
Western blots for RAN peptides
HEK293Tcells were transfected with one of the following plasmids that express tagged RAN and anti-rabbit HRP (1:10,000) for 2 hours at room temperature, the bands were detected using the SuperSignal™ West Femto Maximum Sensitivity Substrate as per manufacturers protocol 9 .
Recombinant AAV production
Viral production was achieved through transfection of HEK293T cells cultured in 150mm plates with the pAAV6 serotype packaging plasmid 49 , pXX6 helper plasmid that contains the adenovirus E4, VA and E2a helper regions 50 and AAV2-ITR containing plasmid expressing dSaCas9 and the control or (CAG) 6 gRNA (generated from the SaCas9 plasmid pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA, Addgene #61591). Transfections were carried out using the TransIT-LT1 transfection reagent and recommended protocols (MirusBio). Cells were harvested between 48h and 72h post-transfection, recombinant AAV2/6 virus was purified by iodixanol step gradients followed by vector concentration and buffer exchange with lactated Ringer's in an Apollo 150kDa concentrator (Orbital Biosciences) 51 . Virus titers were determined using the Quant-iT Picogreen dsDNA assay kit (Life Technologies) 52 and found to be ~10 11 vg/mL.
Isolation of single muscle fibers
Single muscle fibers were isolated from 3-4 week old HSA LR mice as described previously 53 .
Briefly, the EDL was dissected and digested with a 0.2% Collagenase Type I in DMEM solution in a 37 0 C water bath for 1 hour without agitation. The digested muscle was then flushed with DMEM to separate out individual muscle fibers. Fibers were cultured in DMEM containing 20% FBS overnight before infection with AAV.
Transduction of human DM1 myoblasts and isolated HSA LR muscle fibers
Virus carrying dSaCas9 and control or (CAG) 6 gRNA was used to infect human DM1 primary myoblast cell lines and HSA LR mouse EDL muscle fibers. To determine whether blocking expression of the CTG repeats in the human myoblasts affected the presence of RNA foci and splicing of MBNL targets, cells were grown to 60% confluency on CC2 chamber slides and infected for 6 days (3 days in growth media plus 3 days in differentiation media) with viral titers of 10 9 . To analyze the effects on RNA foci in HSA LR muscle fibers, 10-20 muscle fibers were cultured in wells of a 96 well plate and infected with a 10 9 viral titer for 48h.
Quantitation of Signal Intensity of Nuclear Foci in Mouse Muscle Fibers
Python scripts were written to quantitate intensity of FISH signal from RNA foci within nuclei of muscle fibers (python functions are listed below, and also see Fig. S5 ). Regions of interest were defined across each tile-scanned z-stack image obtained by confocal imaging. To identify and segment nuclei, 16-bit intensity values were scaled to lie between 0 and 1 (skimage.img_as_float). Then, a gaussian filter of standard deviation 3 pixels was applied to the raw DAPI signal (skimage.filters.gaussian), and a threshold of mean + 5 * standard deviation of the gaussian filtered signal was used to generate a binary mask. Holes were filled (scipy.ndimage.fill_holes), and a binary opening operation was performed to remove salt noise (skimage.morphology.binary_opening with ball structured element of radius 2). Nuclei were segmented and labeled (skimage.measure.label), and objects with pixel volume <1000 or >20000 were removed. FISH signal was scaled to lie between 0 and 1 as above, and a grayscale opening operation was performed to measure background (skimage.morphology.opening with a ball structured element of radius 3). This background intensity multipled by 3 was subtracted from the FISH signal to yield background-subtracted FISH signal. The binary nucleus mask was applied to this signal, and total intensity was measured within each nucleus, and divided by the nuclear volume in pixels, to obtain the final FISH signal per unit volume for each nucleus. This procedure was applied to all regions of interest across all fibers. Figure 5B , events with <1.3 sigmoid fit error and >1 monotonicity Z-score were selected for display. For Figure 5F , only events identified in Figure 5B to lie in the upper right or lower left quadrants were further analyzed; in addition, events were required to exhibit <0.33 difference in Y between cells treated with AAV-dSaCas9-control gRNA and non-DM1 tibialis biopsies. Raw RNA-Seq reads for these libraries are publicly available (GEO accession number pending). Statistics on read coverage are in Table S2 .
Analysis of RNAseq data
Electromyography
To determine whether expression of dCas9-(CAG) 6 rescued myotonia in the HSA LR mice, mice were injected with AAV6-dSaCas9 and control or (CAG) 6 gRNA at 10 10 viral genomes per mouse via the temporal vein at P2 55 . Myotonia was assessed by electromyography at 5 weeks of age.
Electomyography was performed under general anaesthesia (intraperitoneal ketamine, 100 mg/kg; xylazine, 10 mg/kg) using 30 gauge concentric needle electrodes to examine the hindlimb gastrocnemius and tibialis anterior muscles. At least 15 needle insertions were performed in each muscle and myotonic discharges were denoted as a percentage of the total number of insertions.
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